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Experimental
General
Solvents for chromatography and reactions were purchased HPLC grade (except DMF was purchased from Acros, 99.8 %, extra dry over molecular sieves) or distilled over an appropriate drying reagent prior to use. If necessary, solvents were degassed either by freeze--pump--thaw or by bubbling N 2 through the vigorously stirred solution for several minutes. Unless otherwise stated, all other reagents were used without further purification from commercial sources. High--resolution electrospray (ESI) mass spectra were obtained on a Varian MAT 711 MS instrument operating in either positive or negative ionization modes.
LC--MS was performed on an Agilent 1260 Infinity HPLC System, MS--Agilent 1100 Series, Type: 1946D, Model: SL, equipped with a Agilent Zorbax Eclipse Plus C18 (100 x 4.6 mm, particle size 3.5 micron) RP column with a constant flow--rate of 2 mL/min, if not stated otherwise. Retention times (t R ) are given in minutes (min).
HPLC was performed on a Varian Prep Star HPLC System, Model SD--1 equipped with Varian Dynamax columns (RP--Analytical: Microsorb 60 C18, 250 x 4.6 mm, particle size 8 μm; RP--SemiPrep: Microsorb 60 C18, 250 x 21.4 mm, particle size 8 μm; RP--Prep: Microsorb 60 C18, 250 x 41.4 mm, particle size 8 μm). Prior to injection, samples were filtered through a syringe filter (Chromafil Xtra GF100/25, pore size 1 µm).
Synthesis of BGAGs
A. General procedure for attachement of the Azide--functionalized PEG--linker
In a schlenk flask, 8 or N--Boc--D--redAG0 10 (1.1 equiv.), Azido--(PEG) n --NHS--ester (Baseclick, n = 4 (11, #BCL--001), n = 8 (12, #BCL--032), n = 12 (13, #BCL--033); 1.0 equiv.) and DIPEA (2.0 equiv.) were added to degassed, anhydrous DMF (0.5 mL) under N 2 --atmosphere. The reaction mixture was stirred at r.t. while reaction progress was monitored by LCMS. Upon completion, the crude reaction mixture was purified by C18 reverse phase (RP) flash column chromatography (100/0 → 60/40 = 1 mM HCl/MeCN) or by RP--HPLC (MeCN/H 2 O/formic acid = 10/90/0.1 → 80/20/0.1 over 42 min). The product containing fractions were combined, concentrated in vacuo and freeze--dried to obtain the desired product.
B. General procedure for click reaction
In a schlenk flask, the reaction mixture was prepared with the corresponding azide (1.0 equiv.) and BG--alkyne (SI2.1) (1.1 eq) in degassed DMSO (2−4 mL) under N 2 --atmosphere. Stock solutions of sodium ascorbate (NaAsc, 131 mM) and copper--(II)--sulfate pentahydrate (105 mM) were prepared separately in degassed water. 50 µL of each stock solution were mixed under N 2 to preform the catalytically active Cu I species and quickly transferred to the reaction mixture. The resulting reaction mixture was heated to 90 ⁰C and reaction progress was monitored by LCMS. Upon completion, the crude product was purified by RP flash column chromatography (100/0 → 60/40 = 1 mM HCl/MeCN) or RP--HPLC (MeCN/H 2 O/formic acid = 10/90/0.1 → 80/20/0.1 over 42 min). The product containing fractions were combined, concentrated in vacuo and freeze--dried to obtain the desired product.
C. General procedure for Boc--deprotection:
In a falcon tube, neat TFA (250 µL) was added to the Boc--protected molecule and stirred at r.t. for 10 min. Diethylether (50 mL) was added and the resulting suspension was centrifuged (4000 rpm, 20 min, 4 ⁰C). The supernatant was discarded, the solid was washed again with diethylether and finally dried under high vacuum to obtain the desired product. 
N--(4--(((2--Amino--9H--purin--6--yl)oxy)methyl)benzyl)pent--4--ynamide (3)
6
N--(4--(((2--
HRMS (ESI):
UV/Vis (LCMS):
λ max = 290 nm.
(2S,4S)--2--(4--((4--((E)--(4--(2--Aminoacetamido)phenyl)diazenyl)phenyl)amino)--4--oxobutyl)--4--((tert--butoxycarbonyl)amino)pentanedioic acid (6)
6 was prepared according to a literature procedure and analytical data matched the one reported. 
UV/VIS (LCMS)
: λ max (π → π * ) = 368 nm.
(2S,4S)--2--(4--((4--((E)--(4--(2--(3--azidopropanamido)acetamido)phenyl)diazenyl)phenyl)--amino)--4--oxobutyl)--4--((tert--butoxycarbonyl)amino)pentanedioic acid (14)
A schlenk flask was charged with 8 (10 mg, 17 µmol, 1.0 equiv.), HBTU (7.2 mg, 19 µmol, 1.1 equiv.) and 3--azidopropionic acid 3 (3.0 mg, 16 µmol, 1.5 equiv.) under a N 2 --atmosphere. Degassed, anhydrous DMF (1 mL) was added and the reaction mixture was cooled to 0 °C before DIPEA (6.0 µL, 34 µmol, 2.0 equiv.) was added dropwise. The reaction mixture was allowed to warm to r.t. and reaction progress was monitored by LCMS. Upon completion, the crude reaction mixture was purified by RP--HPLC (10/90/0.1 →80/20/0.1 = MeCN/H 2 O/formic acid over 45 min). The product containing fractions were combined, concentrated in vacuo and freeze--dried to obtain 10 mg (15 µmol) of 14 as a yellow solid in 88% yield. UV/VIS (LCMS): λ max (π → π * ) = 368 nm.
H NMR
(2S,4S)--2--Amino--4--(4--((4--((E)--(4--(2--(3--(4--(3--((4--(((2--amino--9H--purin--6--yl)oxy)methyl) benzyl)amino)--3--oxopropyl)--1H--1,2,3--triazol--1--yl)propanamido)acetamido)-
(2S,4S)--2--(4--((4--((E)--(4--((1--Azido--15--oxo--3,6,9,12--tetraoxa--16--azaoctadecan--18--yl)amino)phenyl)diazenyl)phenyl)amino)--4--oxobutyl)--4--((tert--butoxycarbonyl)--amino)pentanedioic acid (15)
15 was prepared according to general procedure A.
Amounts: 
UV/VIS (LCMS)
: λ max (π → π * ) = 368 nm. 
(2S,4S)--2--Amino--4--(4--((4--((E)--(4--(1--(4--(3--((4--(((2--amino--9H--purin--6--yl)oxy)methyl)--benzyl)amino)--3--oxopropyl)--1H--1,2,3--triazol--1--yl)--15--oxo--
UV/VIS (LCMS)
(2S,4S)--2--(4--((4--((E)--(4--((1--
UV/VIS (LCMS)
: λ max (π → π * )= 368 nm. UV/Vis (LCMS): λ max (π ! π*) = 368 nm. UV/Vis (LCMS): λ max (π ! π*) = 369 nm.
(2S,4S)--2--(4--((4--((E)--(4--(1--
(2S,4S)--2--Amino--4--(4--((4--((E)--(4--(1--(4--(3--((4--(((2--amino--9H--purin--6--yl)oxy)methyl)benzyl)amino)--3--oxopropyl)--1H
(2S,4S)--2--(4--((4--((E)--(4--((2--aminoethyl)amino)phenyl)diazenyl)phenyl)amino)--4--oxobutyl)--4--((tert--butoxycarbonyl)amino)pentanedioic acid (10)
2 (200 mg, 0.360 mmol, 1.0 equiv.) and Fmoc--2--aminoacetaldehyde 4 (101 mg, 0.360 mmol, 1.0 equiv.) were dissolved in DCE (10 mL) and one drop of acetic acid was added. Sodium triacetoxyborohydride (270 mg, 1.28 mmol, 3.6 equiv.) was added portionwise and the reaction mixture was stirred at r.t. for 4.5 h. The reaction mixture was quenched and subsequently washed with sat. aq. NaHCO 3 (3x) before the organic layer was concentrated in vacuo.
The residue was redissolved in DMF (47.5 mL), piperidine (2.5 mL) was added and the deprotecting reaction was stirred overnight. The reaction mixture was concentrated in vacuo, the residue was redissolved in EtOAc, washed with sat. aq. NaHCO 3 (2x) and brine (sat.) before the organic layer was dried over MgSO 4 . The solvent was removed in vacuo before purification by flash column chromatography (90/10/1 = DCM/MeOH/TEA) followed by RP column chromatography (100/0 → 60/40 = 1mM HCl/MeCN). The product containing fractions were combined, concentrated in vacuo and freeze--dried to obtain the intermediate bis- In a round bottom flask, dimethyl (2S,4S)- 
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